<?xml version="1.0" encoding="utf-8"?><!DOCTYPE article PUBLIC "-//ES//DTD journal article DTD version 5.0.2//EN//XML" "art502.dtd" [<!ENTITY gr1 SYSTEM "gr1" NDATA IMAGE><!ENTITY gr2 SYSTEM "gr2" NDATA IMAGE><!ENTITY gr3 SYSTEM "gr3" NDATA IMAGE><!ENTITY gr4 SYSTEM "gr4" NDATA IMAGE>]>
<article version="5.0" xml:lang="en" docsubtype="fla">
	<item-info><jid>DAD</jid><aid>3226</aid><ce:pii>S0376-8716(08)00056-2</ce:pii><ce:doi>10.1016/j.drugalcdep.2008.01.015</ce:doi><ce:copyright type="unknown" year="2008"/></item-info>
	<ce:floats>
		<ce:figure id="fig1"><ce:label>Fig. 1</ce:label><ce:caption><ce:simple-para>Flow diagram of patients during the follow-up period.</ce:simple-para></ce:caption><ce:link locator="gr1"/></ce:figure>
		<ce:figure id="fig2"><ce:label>Fig. 2</ce:label><ce:caption><ce:simple-para>a&ndash;c 12-Month retention rates by type of medication (upper panel), and provider setting (middle panel) and length of treatment (lower panel) across weeks of the observation period.</ce:simple-para></ce:caption><ce:link locator="gr2"/></ce:figure>
		<ce:figure id="fig3"><ce:label>Fig. 3</ce:label><ce:caption><ce:simple-para>Rates (percentage of patients) of non-retention, death, and abstinence overall and by setting (<ce:italic>N</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>2442).</ce:simple-para></ce:caption><ce:link locator="gr3"/></ce:figure>
		<ce:figure id="fig4"><ce:label>Fig. 4</ce:label><ce:caption><ce:simple-para>Concomitant drug use (percentage of patients) by provider setting.</ce:simple-para></ce:caption><ce:link locator="gr4"/></ce:figure>
		<ce:table id="tbl1" frame="topbot" rowsep="0" colsep="0"><ce:label>Table 1</ce:label><ce:caption><ce:simple-para>Selected provider characteristics of small PMC, medium and large-scale SSC settings</ce:simple-para></ce:caption><tgroup cols="4"><colspec colname="col1"/><colspec colname="col2"/><colspec colname="col3"/><colspec colname="col4"/><thead valign="top"><row><entry rowsep="1"/><entry rowsep="1" align="left">Type of setting: Small (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>86)</entry><entry rowsep="1" align="left">Type of setting: Medium (<ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>101)</entry><entry rowsep="1" align="left">Type of setting: Large (36)</entry></row></thead><tbody><row><entry namest="col1" nameend="col4" align="left">Physicians orientation</entry></row><row><entry align="left"><ce:hsp sp="1.0"/>% family doctor</entry><entry align="left">79.1%</entry><entry align="left">82.3%</entry><entry align="left">45.7%</entry></row><row><entry align="left"><ce:hsp sp="1.0"/>% psychiatrist/neurologist</entry><entry align="left">14.0%</entry><entry align="left">17.7%</entry><entry align="left">31.4%</entry></row><row><entry align="left"><ce:hsp sp="1.0"/>% other</entry><entry align="left">16.9%</entry><entry align="left">0</entry><entry align="left">22.9%</entry></row><row><entry namest="col1" nameend="col4" align="left"><ce:vsp sp="0.5"/></entry></row><row><entry namest="col1" nameend="col4" align="left">Psychosocial interventions (current)</entry></row><row><entry align="left"><ce:hsp sp="1.0"/>Within setting</entry><entry align="left">8.5%</entry><entry align="left">48.6%</entry><entry align="left">81.3%</entry></row><row><entry align="left"><ce:hsp sp="1.0"/>Outside setting</entry><entry align="left">74.3%</entry><entry align="left">49.6%</entry><entry align="left">32.6%</entry></row><row><entry namest="col1" nameend="col4" align="left"><ce:vsp sp="0.5"/></entry></row><row><entry align="left">Doctors years (mean/S.D.) experience</entry><entry align="left">8.2 (3.9)</entry><entry align="left">8.5 (3.9)</entry><entry align="left">8.5 (4.0)</entry></row><row><entry align="left">Number of current pts (mean/S.D.)</entry><entry align="left">5.1 (2.3)</entry><entry align="left">26.4 (9.7)</entry><entry align="left">118.2 (24.6)</entry></row><row><entry align="left">% pts with urine test weekly</entry><entry align="left">61.1%</entry><entry align="left">57.4%</entry><entry align="left">48.0%</entry></row><row><entry align="left">% pts with take-home prescription</entry><entry align="left">75.4%</entry><entry align="left">57.5%</entry><entry align="left">33.2%</entry></row><row><entry align="left">Average no. of days take-home</entry><entry align="left">2.1 (0.4)</entry><entry align="left">1.9 (0.6)</entry><entry align="left">1.7 (0.6)</entry></row><row><entry align="left">Face-to-face contact/week (mean/S.D.)</entry><entry align="left">3.7 (2.3)</entry><entry align="left">4.9 (2.3)</entry><entry align="left">5.6 (2.1)</entry></row><row><entry align="left">Average duration of contact in minutes (mean/S.D.)</entry><entry align="left">10.9 (7.4)</entry><entry align="left">9.9 (6.8)</entry><entry align="left">10.9 (7.6)</entry></row></tbody></tgroup></ce:table>
	</ce:floats>

<head>
	<ce:title>Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients</ce:title>
	<ce:author-group><ce:author><ce:given-name>Hans-Ulrich</ce:given-name><ce:surname>Wittchen</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="cor1"><ce:sup>&#x204E;</ce:sup></ce:cross-ref><ce:e-address type="email">wittchen@psychologie.tu-dresden.de</ce:e-address><ce:e-address type="email">wittchen@mpipsykl.mpg.de</ce:e-address></ce:author><ce:author><ce:given-name>Sabine M.</ce:given-name><ce:surname>Apelt</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Michael</ce:given-name><ce:surname>Soyka</ce:surname><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Markus</ce:given-name><ce:surname>Gastpar</ce:surname><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Markus</ce:given-name><ce:surname>Backmund</ce:surname><ce:cross-ref refid="aff6"><ce:sup>f</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>J&ouml;rg</ce:given-name><ce:surname>G&ouml;lz</ce:surname><ce:cross-ref refid="aff7"><ce:sup>g</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Michael R.</ce:given-name><ce:surname>Kraus</ce:surname><ce:cross-ref refid="aff8"><ce:sup>h</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Felix</ce:given-name><ce:surname>Tretter</ce:surname><ce:cross-ref refid="aff9"><ce:sup>i</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Martin</ce:given-name><ce:surname>Sch&auml;fer</ce:surname><ce:cross-ref refid="aff10"><ce:sup>j</ce:sup></ce:cross-ref><ce:cross-ref refid="aff11"><ce:sup>k</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jens</ce:given-name><ce:surname>Siegert</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Norbert</ce:given-name><ce:surname>Scherbaum</ce:surname><ce:cross-ref refid="aff12"><ce:sup>l</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>J&uuml;rgen</ce:given-name><ce:surname>Rehm</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff5"><ce:sup>e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Gerhard</ce:given-name><ce:surname>B&uuml;hringer</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Institute of Clinical Psychology and Psychotherapy, Technische Universitaet Dresden, Chemnitzerstrasse 46, 01187 Dresden, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Psychiatric Hospital, University of Munich, Nussbaumstrasse 7, 80336 Munich, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>c</ce:label><ce:textfn>IFT Institute for Therapy Research, Parzivalstrasse 25, 80804 M&uuml;nchen, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>d</ce:label><ce:textfn>Fliedner Klinik Berlin, Charlottenstrasse 65, 10117 Berlin, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff5"><ce:label>e</ce:label><ce:textfn>Centre for Addiction and Mental Health, 33 Russell Street, Toronto, Ontario, Canada M5S 2S1</ce:textfn></ce:affiliation><ce:affiliation id="aff6"><ce:label>f</ce:label><ce:textfn>Institut f&uuml;r Suchtmedizin und Adipositas, Tal 9, 80331 M&uuml;nchen, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff7"><ce:label>g</ce:label><ce:textfn>Praxiszentrum Kaiserdamm, Kaiserdamm 24, 14057 Berlin, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff8"><ce:label>h</ce:label><ce:textfn>Kreiskliniken Alt&ouml;tting-Burghausen, Krankenhausstrasse 1, 84489 Burghausen, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff9"><ce:label>i</ce:label><ce:textfn>Isar-Amper-Klinikum, Klinikum M&uuml;nchen-Ost, Kompetenzzentrum Sucht, Postfach 1111, 85529 M&uuml;nchen Haar, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff10"><ce:label>j</ce:label><ce:textfn>Klinik f&uuml;r Psychiatrie, Psychotherapie und Suchtmedizin, Kliniken-Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff11"><ce:label>k</ce:label><ce:textfn>Klinik f&uuml;r Psychiatrie und Psychotherapie, Charit&eacute; Campus Mitte, Charit&eacute; Universit&auml;tsmedizin Berlin, Charit&eacute;platz 1, 10117 Berlin, Germany</ce:textfn></ce:affiliation><ce:affiliation id="aff12"><ce:label>l</ce:label><ce:textfn>Klinik f&uuml;r abh&auml;ngiges Verhalten und Suchtmedizin, Rheinische Kliniken Essen, Institut der Universit&auml;t Duisburg-Essen, Virchowstrasse 174, 45147 Essen, Germany</ce:textfn></ce:affiliation><ce:correspondence id="cor1"><ce:label>&#x204E;</ce:label><ce:text>Corresponding author. Tel.: +49 351 463 36983; fax: +49 351 463 36984.</ce:text></ce:correspondence>
	</ce:author-group>
	<ce:date-received day="30" month="4" year="2007"/><ce:date-revised day="17" month="1" year="2008"/><ce:date-accepted day="20" month="1" year="2008"/>
	<ce:abstract>
		<ce:section-title>Abstract</ce:section-title>
		<ce:abstract-sec><ce:section-title>Background</ce:section-title><ce:simple-para>In many countries, buprenorphine and methadone are licensed for the maintenance treatment (MT) of opioid dependence. Despite many short-term studies, little is known about the long-term (12-month) effects of these treatments in different settings, i.e. primary care-based (PMC) and specialized substitution centers (SSCs).</ce:simple-para></ce:abstract-sec>
		<ce:abstract-sec><ce:section-title>Objectives</ce:section-title><ce:simple-para>To describe over a period of 12 months: (1) mortality, retention and abstinence rates; (2) changes in concomitant drug use, somatic and mental health; and (3) to explore differences between different types of provider settings.</ce:simple-para></ce:abstract-sec>
		<ce:abstract-sec><ce:section-title>Methods</ce:section-title><ce:simple-para>12-Month prospective-longitudinal naturalistic study with four waves of assessment in a prevalence sample of <ce:italic>N</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>2694 maintenance patients, recruited from a nationally representative sample of <ce:italic>N</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>223 substitution physicians.</ce:simple-para></ce:abstract-sec>
		<ce:abstract-sec><ce:section-title>Results</ce:section-title><ce:simple-para>The 12-month retention rate was 75%; the mortality rate 1.1%. 4.1% of patients became &ldquo;abstinent&rdquo; during follow-up. 7% were referred to drug-free addiction treatment. Concomitant drug use decreased and somatic health status improved. No significant improvements were observed for mental health and quality of life. When controlling for initial severity, small PMC settings revealed better retention, abstinence and concomitant drug use rates.</ce:simple-para></ce:abstract-sec>
		<ce:abstract-sec><ce:section-title>Conclusion</ce:section-title><ce:simple-para>The study underlines the overall 12-month effectiveness of various forms of agonist MT. Findings reveal relatively high retention rates, low mortality rates, and improvements in most 12-month outcome domains, except for mental health and quality of life. PMC settings appear to be a good additional option to improve access to MTs.</ce:simple-para>
		</ce:abstract-sec>
	</ce:abstract>
	<ce:keywords class="keyword">
		<ce:section-title>Keywords</ce:section-title>
		<ce:keyword><ce:text>Methadone</ce:text></ce:keyword>
		<ce:keyword><ce:text>Buprenorphine</ce:text></ce:keyword>
		<ce:keyword><ce:text>Epidemiology</ce:text></ce:keyword>
		<ce:keyword><ce:text>Opioid dependence</ce:text></ce:keyword>
		<ce:keyword><ce:text>Course</ce:text></ce:keyword>
		<ce:keyword><ce:text>Outcome</ce:text></ce:keyword>
	</ce:keywords>
</head>
<body>
	<ce:sections>
	<ce:section><ce:label>1</ce:label>
	<ce:section-title>Introduction</ce:section-title>
	<ce:para>Considerable changes have occurred in the treatment and care structure for opioid addicts over the past decade. In addition to a wide range of existing drug-free psychosocial abstinence programs (<ce:cross-refs refid="bib21 bib33">McLellan et al., 1993; Vollmer and Krauth, 2001</ce:cross-refs>), increased emphasis was placed in the last decade on establishing outpatient methadone maintenance therapy (MMT) and buprenorphine maintenance therapy (BMT) for the management of opioid-dependent individuals. Maintenance treatments (MTs) are provided by either large-scale specialized substitution centers (SSCs) or, more recently, by office-based physicians who either specialize fulltime on MMT/BMT treatment provision or who treat a few maintenance patients only, mostly within the context of their main function as primary care doctors (<ce:cross-refs refid="bib5 bib22 bib36">Gossop et al., 2003; Merrill, 2002; Wittchen et al., 2005</ce:cross-refs>). The primary short-term goals of treatment are retention in treatment, reduction of medical and social-behavioral risks, reduction of harm and mortality associated with injecting and other concomitant drug use, and interruption of the vicious circles of drug intake and criminal acts. By involving patients in a continuous treatment plan, it is also expected to reduce the burden of associated mental and somatic morbidities (psychosis, depression, HIV, viral hepatitis, etc.) and the substantial social sequelae as intermediate goals. The controversial long-term goal of maintenance regimen is &ndash; in some countries explicitly &ndash; to help patients to ultimately quit the use of drugs entirely (abstinence) and to prepare them for the decision to enroll in a drug-free abstinence program. However, due to the lack of long-term data, it is unclear to what degree this goal is realistic.</ce:para>
	<ce:para>Agonist maintenance therapies with methadone or more recently buprenorphine are currently the two most frequently used maintenance treatment strategies for opioid dependence in the care system. In clinical trials, both flexible-dose MMT and BMT have been shown to be consistently effective in at least reducing illicit opioid use (<ce:cross-refs refid="bib11 bib17 bib31 bib1">Johnson et al., 1992; Ling et al., 1976; Strain et al., 1994; Connock et al., 2007</ce:cross-refs>). In combination with various degrees of psychosocial support and psychological treatment other beneficial outcomes have also been demonstrated in clinical studies (review by <ce:cross-refs refid="bib1 bib36 bib3 bib4 bib12 bib13 bib16 bib18 bib19 bib20 bib24 bib29 bib34">Connock et al., 2007; Wittchen et al., 2005; Gerra et al., 2004; Gossop et al., 2001; Kakko et al., 2003; King et al., 2002; Layson-Wolf et al., 2002; Ling and Wesson, 2003; Mattick et al., 2003, 2004; Poser and Poser, 1996; Soyka et al., 1997; Waal and Haga, 2003</ce:cross-refs>), for example, with regard to (a) improvement of the social situation, (b) reduction of drug-related crime, (c) reduction of morbidity and mortality rates, and (d) reduction of the transmission rate of HIV.</ce:para>
	<ce:para>Despite a considerable body of research (i.e. <ce:cross-refs refid="bib1 bib4 bib5 bib13">Connock et al., 2007; Gossop et al., 2001, 2003; King et al., 2002</ce:cross-refs>), several significant research deficits impede further progress. First, a lack of longitudinal studies in samples of unselected substitution settings and unselected samples of patients that inform us about how MT works under routine care conditions (<ce:cross-refs refid="bib15 bib1">Law and Nutt, 2003; Connock et al., 2007</ce:cross-refs>) and about the degree to which the assumed intermediate and long-term goals are reached in everyday practice. This deficit is regarded as an obstacle for the wider implementation of maintenance programs (<ce:cross-ref refid="bib15">Law and Nutt, 2003</ce:cross-ref>). Second, there is some evidence that the beneficial effects of MMT and BMT might be robust across different types of treatment settings. However the effects of different provider models and formats remain understudied, especially with regard to subgroups of addicts. Most available studies were undertaken in a few countries (US, UK, Australia) that have considerably different regulations and traditions than other countries (<ce:cross-ref refid="bib1">Connock et al., 2007</ce:cross-ref>). The German treatment system, for example, has been relatively slow in adopting MMT and BMT as first-line treatments for opioid-dependent individuals. Due to the existence of a wide range of specialized in- and outpatient long-term treatment programs established in the 1970s and 1980s, MMT programs were quite rare until the 1990s and were mainly provided by relatively few SSCs with quite restrictive regulations of access (<ce:cross-refs refid="bib33 bib36">Vollmer and Krauth, 2001; Wittchen et al., 2005</ce:cross-refs>). Although access to treatment programs remain up to now heavily regulated and rigidly controlled with quite restrictive criteria and quality assurance measures for access and management of patients, the number of institutions licensed to administer MMT and BMT have been largely increased during the past decade. Currently (2005) in Germany there are about 2500 medical doctors (with more than 65,000 maintenance patients), trained and licensed for MT, constituting a twofold increase over the rates before the year 2000 (<ce:cross-ref refid="bib36">Wittchen et al., 2005</ce:cross-ref>). This increase is mainly due to increasing number of smaller office-based physicians providing maintenance treatment. Stimulated by the availability of buprenorphine (<ce:cross-ref refid="bib2">Farell et al., 2000</ce:cross-ref>) and by evidence that maintenance in primary care settings may work (<ce:cross-refs refid="bib4 bib5 bib22 bib26">Gossop et al., 2001, 2003; Merrill, 2002; Salsitz et al., 2000</ce:cross-refs>), MMT and BMT in particular is increasingly offered by primary care doctors (PMC settings) or less frequently by psychiatrists and other specialists that frequently do not generally specialize on MMT and BMT, but rather manage only a few such patients within the context of their predominant and main function as a family doctor or specialist. Such PMC settings might differ in a number of aspects (e.g. climate, resources, expertise) that can be expected to affect quality of care and outcome. For example they typically do not have additional resources in terms of time, personnel and expertise to directly offer particularly the mandatory psychological and social interventions. Irrespective of this, these doctors have to follow, though, the same stringently enforced complex legislative regulations as specialized MT centers for example by collaboration with other institutions. The relative risks and benefits of maintenance treatments in such PMC contexts remain clearly understudied (<ce:cross-refs refid="bib36 bib22">Wittchen et al., 2005; Merrill, 2002</ce:cross-refs>).</ce:para>
</ce:section>
<ce:section><ce:label>3.2</ce:label><ce:section-title>Retention rates and time to drop out</ce:section-title><ce:para><ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>a&ndash;c<ce:float-anchor refid="fig2"/> show the retention rates from baseline to 1-year follow-up, excluding <ce:italic>n</ce:italic><ce:hsp sp="0.25"/>=<ce:hsp sp="0.25"/>274 patients that terminated the maintenance program because of either abstinence or referral to abstinence programs. Adjusted for differences between groups with regard to prior treatment duration, both medication groups reveal a steady decline of retention over the 52 weeks observation time of about 25%. <ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>c reveals that retention during the follow-up period is associated with length of previous retention in the treatment before baseline. Patients who had just started their current maintenance therapy in the 4 weeks prior to baseline, irrespective of type of medication, had the lowest retention rate as compared to patients with &gt;6 month (82%) prior treatment (61%, HR: 2.7; 95% CI: 2.1&ndash;4.4), followed by patients with 2&ndash;6 months prior treatment (70%, HR: 2.0 95% CI: 1.6&ndash;2.4). <ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>b reveals better long-term retention in PMC settings as compared to SSC (HR: 1.4, 95% CI: 1.1&ndash;1.7) largely due to changes after week 42. Reasons for not retaining patients in therapy were similar in most subgroups examined, except for the methadone group, for which more patients were not retained because of imprisonment (HR: 1.7; 95% CI: 1.3&ndash;2.5).</ce:para></ce:section>
</ce:sections>
	<ce:acknowledgment>
	<ce:section-title>Acknowledgements</ce:section-title>
		<ce:para>This study is part of the collaborative COBRA study (Cost-Benefit and Risk Appraisal of Substitution Treatments, <ce:inter-ref xlink:href="http://www.cobra-projekt.de/">www.cobra-projekt.de</ce:inter-ref>), supported by the German Federal Ministry of Research and Technology (BMBF No. 01EB0440-0441/01EB0142) as part of the Addiction Research Network &ldquo;ASAT&rdquo; (<ce:inter-ref xlink:href="http://www.asat-verbund.de/">www.asat-verbund.de</ce:inter-ref>). The field work and health economic program components were further supported by an unrestricted educational grant from essex pharma GmbH, Germany. We wish to thank all doctors and staff members of the participating clinics for their continued support and collaboration. <ce:italic>Contributors</ce:italic>. Hans-Ulrich Wittchen has planned the investigation and written the manuscript. Sabine M. Apelt provided substantial contribution to the writing of the manuscript. Dr. G&ouml;lz has participated in the recruitment of study participants and has provided counselling for the conceptualisation of the study questionnaires. Dr. Tretter provided substantial contribution to the writing of the manuscript, the interpretation, and the discussion of the results. Jens Siegert has planned and conducted the statistical analysis. J&uuml;rgen Rehm has provided substantial comments on the writing of the manuscript as well as consulting for the statistical analysis and its presentation. Gerhard B&uuml;hringer provided substantial contribution to the writing of the manuscript. Prof. Scherbaum was responsible for carrying out the study in one of the participating centers. He provided substantial contribution to the writing of the manuscript. Dr. Sch&auml;fer and Profs. Kraus, Gastpar, and Soyka provided supervision of and substantial contribution to the writing of the manuscript.</ce:para>
	</ce:acknowledgment>
</body>
<tail>
	<ce:bibliography><ce:section-title>References</ce:section-title>
	<ce:bibliography-sec>
	<ce:bib-reference id="bib1"><ce:label>Connock et al., 2007</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>M.</ce:given-name><ce:surname>Connock</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Juarez-Garcia</ce:surname></sb:author><sb:author><ce:given-name>S.</ce:given-name><ce:surname>Jowett</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Frew</ce:surname></sb:author><sb:author><ce:given-name>Z.</ce:given-name><ce:surname>Liu</ce:surname></sb:author><sb:author><ce:given-name>R.J.</ce:given-name><ce:surname>Taylor</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Fry-Smith</ce:surname></sb:author><sb:author><ce:given-name>E.</ce:given-name><ce:surname>Day</ce:surname></sb:author><sb:author><ce:given-name>N.</ce:given-name><ce:surname>Lintzeris</ce:surname></sb:author><sb:author><ce:given-name>T.</ce:given-name><ce:surname>Roberts</ce:surname></sb:author><sb:author><ce:given-name>A.</ce:given-name><ce:surname>Burls</ce:surname></sb:author><sb:author><ce:given-name>R.S.</ce:given-name><ce:surname>Taylor</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Health Technol. Assess.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:issue-nr>9</sb:issue-nr><sb:date>2007</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>171</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference>
	<ce:bib-reference id="bib23"><ce:label>Mintzer and Stitzer, 2002</ce:label><sb:reference><sb:contribution><sb:authors><sb:author><ce:given-name>M.-Z.</ce:given-name><ce:surname>Mintzer</ce:surname></sb:author><sb:author><ce:given-name>M.-L.</ce:given-name><ce:surname>Stitzer</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Cognitive impairment in methadone maintenance patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Drug Alcohol Depend.</sb:maintitle></sb:title><sb:volume-nr>67</sb:volume-nr></sb:series><sb:issue-nr>1</sb:issue-nr><sb:date>2002</sb:date></sb:issue><sb:pages><sb:first-page>41</sb:first-page><sb:last-page>51</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference>
	</ce:bibliography-sec></ce:bibliography>
</tail>
</article>
